Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
e.l.f. Beauty
ELF
|
+$676M |
| 2 |
UnitedHealth
UNH
|
+$402M |
| 3 |
AutoZone
AZO
|
+$339M |
| 4 |
Kaspi.kz JSC
KSPI
|
+$269M |
| 5 |
Enphase Energy
ENPH
|
+$268M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.12B |
| 2 |
Spotify
SPOT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$619M |
| 4 |
Teradyne
TER
|
+$540M |
| 5 |
Shopify
SHOP
|
+$408M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 29.35% |
| 2 | Technology | 27.26% |
| 3 | Communication Services | 14.16% |
| 4 | Healthcare | 13.89% |
| 5 | Financials | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
CRISPR Therapeutics
CRSP
$4.99B
| $21.9M | 0.02% |
405,425
+9,510
| +2% | +$550K |
|
177
Booking.com
BKNG
$156B
| $21.9M | 0.02% |
138,100
+41,875
| +44% | +$6.2M |
|
178
RxSight
RXST
$253M
| $21.6M | 0.02% |
358,215
+291,733
| +439% | +$16.7M |
|
179
KE Holdings
BEKE
$18.7B
| $20.4M | 0.02% |
1,444,247
-19,381
| -1% | -$304K |
|
180
Rexford Industrial Realty
REXR
$8.14B
| $20.3M | 0.02% |
454,763
-142,292
| -24% | -$6.41M |
|
181
BlackLine
BL
$1.74B
| $20M | 0.02% |
412,483
-195,982
| -32% | -$10.8M |
|
182
Burford Capital
BUR
$942M
| $19.8M | 0.02% |
1,534,668
+207,157
| +16% | +$3.04M |
|
183
Ares Capital
ARCC
$14.1B
| $19M | 0.01% |
913,639
-270,010
| -23% | -$5.64M |
|
184
Clear Secure
YOU
$5.46B
| $18.7M | 0.01% |
1,000,000
| – | – |
|
185
Aehr Test Systems
AEHR
$3.25B
| $18.7M | 0.01% |
1,670,590
+841,964
| +102% | +$9.81M |
|
186
Digimarc Corp
DMRC
$171M
| $18.6M | 0.01% |
598,322
-122,505
| -17% | -$3.11M |
|
187
Ambarella
AMBA
$3.68B
| $17.6M | 0.01% |
326,236
-176,643
| -35% | -$8.78M |
|
188
Brookfield
BN
$108B
| $16.8M | 0.01% |
607,424
| – | – |
|
189
Carlisle Companies
CSL
$15.2B
| $16.8M | 0.01% |
41,349
-2,746
| -6% | -$1.11M |
|
190
Trupanion
TRUP
$1.24B
| $16.6M | 0.01% |
565,800
-130,450
| -19% | -$3.45M |
|
191
Progressive
PGR
$125B
| $16M | 0.01% |
77,056
| – | – |
|
192
Brookfield Renewable
BEPC
$6.19B
| $15M | 0.01% |
529,766
-248,864
| -32% | -$6.96M |
|
|
ADAP
193
DELISTED
Adaptimmune Therapeutics
ADAP
| $14.8M | 0.01% |
15,149,203
-722,672
| -5% | -$793K |
|
194
Beam Therapeutics
BEAM
$2.81B
| $14.6M | 0.01% |
623,640
-128,754
| -17% | -$3.16M |
|
|
NBTX
195
Nanobiotix
NBTX
$1.92B
| $14.3M | 0.01% |
2,869,030
| – | – |
|
196
Waters Corp
WAT
$39.2B
| $14M | 0.01% |
48,249
-2,385
| -5% | -$761K |
|
197
Charles River Laboratories
CRL
$12.7B
| $14M | 0.01% |
67,537
+3
| +0% | +$680 |
|
198
TJX Companies
TJX
$179B
| $13.9M | 0.01% |
126,549
| – | – |
|
|
CFLT
199
DELISTED
Confluent
CFLT
| $13.2M | 0.01% |
447,958
+4,283
| +1% | +$123K |
|
200
Oscar Health
OSCR
$8B
| $13M | 0.01% |
822,088
| – | – |
|
Similar funds
Baillie Gifford & Co's Q2 2024 Portfolio in Review
As of Q2 2024, Baillie Gifford & Co held 303 positions worth $128B, down 0.15% from $129B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Baillie Gifford & Co withdrew a net $5.32B in Q2 2024, closing 18 positions and reducing 164 holdings. Its most notable exit was Baidu, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, up from 27% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Baillie Gifford & Co opened a new position in e.l.f. Beauty worth $802M.
- Baillie Gifford & Co's largest Q2 2024 buy was e.l.f. Beauty: 3,804,541 shares worth $802M.
- Baillie Gifford & Co added most to UnitedHealth in Q2 2024, an estimated $402M increase.
- Baillie Gifford & Co's biggest Q2 2024 reduction was NVIDIA, cutting an estimated $2.12B.
- Baillie Gifford & Co fully exited Baidu in Q2 2024, selling an estimated $271M.
- Baillie Gifford & Co's ten largest holdings make up 42% of its $128B portfolio in Q2 2024.
- Baillie Gifford & Co opened 13 new positions and closed 18 in Q2 2024.
- Baillie Gifford & Co's portfolio value fell 0.15% quarter-over-quarter to $128B.
Based on Baillie Gifford & Co's 13F filing for Q2 2024, filed 25 Jul 2024.